Medical Field: Pediatrics
Award: Special Award Winner
Country: Austria
Edition: 6. IMA
Award: Special Award Winner
Country: Austria
Edition: 6. IMA
Research Work: Interleukin 2 with anti-GD2 antibody ch14.18/ CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial
Published in: The Lancet Oncology
Prof. Ruth Ladenstein, MD, PhD, paediatrician and oncologist from the Children’s Cancer Research Institute Vienna, has been devoting her whole career to research of neuroblastoma. Together with an international group of colleagues she researched and proved the safety and efficacy of dinutuximab beta immunotherapy in first-line treatment of patients with high-risk neuroblastoma.
Only cooperation and collaboration will lead to achievements. One of the reasons I am here is to widen the European reference network of paediatric oncology, which strives to align treatment outcomes across Europe, so that all children have equal access to quality treatment.